Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower… (More)
DOI: 10.1016/j.leukres.2013.11.016

Topics

Cite this paper

@article{Odwyer2014Nilotinib3M, title={Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.}, author={M O'dwyer and Ronan Swords and Arnon Nagler and Mary Frances McMullin and Philipp le Coutre and Stephen E Langabeer and Alberto Alvarez-Iglesias and Hongxin Li Yushun Fan and Richard Woodman and Francis Joseph Giles and Eibhlin A Conneally}, journal={Leukemia research}, year={2014}, volume={38 3}, pages={310-5} }